Despite the demonstrated efficacy of immunotherapy in many patients with NSCLC, those with poor performance status (PS) do not enjoy the same survival benefit, an Australian study has shown. Findings from a retrospective study of nivolumab therapy in 66 South Australian patients with advanced NSCLC suggest careful assessment of patients is warranted before initiating immunotherapy, ...
Performance status a limiting factor for immunotherapy in NSCLC: SA study
By Mardi Chapman
7 Jul 2021